IBD Pharmaceutical Composition With Dose-Guided Plasma Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory bowel disease, such as 5-ASA preparations, corticosteroids, and anti-α4β7 integrin antibodies, are insufficiently effective, have complex pharmacokinetics, high production costs, and induce secondary inefficacies due to anti-drug antibodies, while low-molecular-weight compounds face challenges in predicting effective dosages due to interactions with various substances in vivo.
Innovation Solution
A pharmaceutical composition comprising a compound represented by formula (I) or its pharmaceutically acceptable salt, administered at specific doses ranging from 50 mg to 800 mg per day, preferably in oral or self-emulsifying forms, to achieve plasma concentrations of Compound (2) above 1.9 ng/mL, effectively treating inflammatory bowel disease, particularly ulcerative colitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-α4β7 integrin antibody preparations are used, then treatment effectiveness is improved, but production costs increase and secondary inefficacy occurs due to anti-drug antibodies
Solution Approach 1:
The patent replaces expensive, long-lasting antibody preparations with a low-molecular-weight compound that is metabolized and excreted naturally. Compound (1) has a molecular weight of approximately 300-400 Da compared to antibodies which are 150,000-200,000 Da, making it significantly cheaper to produce while avoiding immunogenicity issues that cause secondary inefficacy with repeated antibody administration
2Ease of manufacture
If low-molecular-weight compounds are used, then production costs are reduced, but effective dosage prediction becomes difficult due to complex pharmacokinetics and interactions with substances in vivo
Solution Approach 1:
The patent establishes specific dosage parameters (50-800 mg/day) and plasma concentration thresholds (trough value ≥1.9 ng/mL) for Compound (1) based on systematic pharmacokinetic studies. The self-emulsifying preparation formulation standardizes absorption, converting the complex pharmacokinetic behavior into predictable, controllable parameters that guide clinical dosing decisions
3Ease of operation
If conventional treatments (5-ASA preparations and corticosteroids) are used, then treatment simplicity is maintained, but effectiveness is insufficient for many patients
Solution Approach 1:
The patent introduces a new chemical compound with distinct pharmacological properties from conventional 5-ASA and corticosteroid treatments. Compound (1) targets different inflammatory pathways, providing effectiveness for patients who fail conventional therapies while maintaining oral administration simplicity and avoiding the severe side effects associated with long-term corticosteroid use
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
To provide a pharmaceutical composition having a dosage of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is effective in the treatment of inflammatory bowel disease. Disclosed is a pharmaceutical composition for treating inflammatory bowel disease, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound or a pharmaceutically acceptable salt thereof is administered to a human in an amount of 50 mg or more as an active ingredient per day. (R represents a hydroxy group or an isobutyloxy group.)